Related Experiment Video

Updated: Jun 6, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting endocrine resistance: is there a role for mTOR inhibition?

Amna Sheri1, Lesley-Ann Martin, Stephen Johnston

  • 1Breast Unit, Royal Marsden Hospital, 123 Old Brompton Road, London, United Kingdom. amna.sheri@icr.ac.uk

Clinical Breast Cancer
|December 1, 2010
PubMed

Insights

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is crucial in cancer. Combining endocrine therapy with mTOR inhibitors shows promise for endocrine-resistant breast cancer, requiring biomarker validation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The PI3K/Akt/mTOR pathway regulates cell proliferation and survival, and its dysregulation is common in cancers.
  • Endocrine resistance is a significant challenge in breast cancer treatment.
  • This pathway plays a role in the development of endocrine-resistant breast cancer.

Purpose of the Study:

  • To review the role of the PI3K/Akt/mTOR pathway in endocrine-resistant breast cancer.
  • To discuss preclinical and clinical studies combining endocrine therapy with mTOR inhibition.
  • To highlight the importance of clinical trial design, tumor selection, and biomarker validation.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of signaling pathways involved in endocrine resistance.
  • Discussion of therapeutic strategies combining endocrine therapy and mTOR inhibitors.

Main Results:

  • Deregulated PI3K/Akt/mTOR signaling is implicated in endocrine-resistant breast cancer.
  • Combining endocrine therapy with mTOR inhibitors is a promising therapeutic strategy.
  • Biomarker identification and appropriate patient selection are critical for treatment success.

Conclusions:

  • Targeting the PI3K/Akt/mTOR pathway offers a potential approach to overcome endocrine resistance in breast cancer.
  • Future research should focus on understanding compensatory mechanisms and optimizing combination therapies.
  • Clinical trials with robust designs and validated biomarkers are essential to advance this treatment strategy.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...